Skip to main content
SpringerLink
Log in

Lipid-lowering drugs and risk for cancer

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The suspicion that lipid-lowering drugs might increase the risk for cancer has been present for three decades and has been the reason for intense debate and several attempts to reanalyze data from clinical trials. Recently, the results of the Simvastatin and Ezetimibe in Aortic Stenosis study sparked new interest in this problem, as the intense lipid-lowering therapy seems to have increased the number of cancers compared with the control group. This article gives an overview of the clinical evidence from trials and observational studies. As of now, the evidence is inconclusive, but there does not appear to be a reason for serious concern with short-term therapy. Whether statins and other lipid-lowering drugs will increase the risk of cancer when used over several decades is at present unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jacobs D, Blackburn H, Higgins M, et al.: Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 1992, 86:1046–1060.

    PubMed  CAS  Google Scholar 

  2. Chen Z, Peto R, Collins R, et al.: Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991, 303:276–282.

    Article  PubMed  CAS  Google Scholar 

  3. Committee of Principal Investigators: A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978, 40:1069–1118.

    Article  Google Scholar 

  4. Committee of Principal Investigators: WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984, 324:600–604.

    Article  Google Scholar 

  5. Davey Smith G, Pekkanen J: Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992, 304:431–434.

    Article  PubMed  CAS  Google Scholar 

  6. Hulley SB, Walsh JM, Newman TB: Health policy on blood cholesterol. Time to change directions. Circulation 1992, 86:1026–1029.

    PubMed  CAS  Google Scholar 

  7. Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: a quantitative review od primary prevention trials. BMJ 1990, 301:309–314.

    Article  PubMed  CAS  Google Scholar 

  8. Oliver MF: Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991, 337:1529–1531.

    Article  PubMed  CAS  Google Scholar 

  9. Drazen JM, D’Agostino RB, Ware JH, et al.: Ezetimibe and cancer-an uncertain association. N Engl J Med 2008, 359:1398–1399.

    Article  PubMed  CAS  Google Scholar 

  10. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. BMJ 1994, 308:373–379.

    PubMed  CAS  Google Scholar 

  11. Scandinavian Simvastatin Survival Study (4S) Group: Randomized trial of cholesterol-lowering in 4444 patients with coronary heart-disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

    Google Scholar 

  12. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  13. ALLHAT Officers and Coordinators: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998–3042.

    Article  Google Scholar 

  14. The LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

    Article  Google Scholar 

  15. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  16. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55–60.

    Article  PubMed  CAS  Google Scholar 

  17. Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  Google Scholar 

  18. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007, 50:409–418.

    Article  PubMed  CAS  Google Scholar 

  19. Cannon CP, Braunwald E, Mccabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  20. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes-phase Z of the A to Z trial. JAMA 2004, 292:1307–1316.

    Article  PubMed  Google Scholar 

  21. Larosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  22. Pedersen TR, Faergeman O, Kastelein JJ, et al.: High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437–2445.

    Article  PubMed  CAS  Google Scholar 

  23. Holdaas H, Fellström B, Jardine AG, et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024–2031.

    Article  PubMed  CAS  Google Scholar 

  24. Browning DR, Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2006, 120:833–843.

    Article  Google Scholar 

  25. Karp I, Behlouli H, LeLorier J, Pilote L: Statins and cancer risk. Am J Med 2008, 121:302–309.

    Article  PubMed  CAS  Google Scholar 

  26. Kuoppala J, Lamminpää A, Pukkala E: Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008, 44:2122–2132.

    Article  PubMed  CAS  Google Scholar 

  27. Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184–2192.

    Article  PubMed  CAS  Google Scholar 

  28. Einhorn N, Eklund G, Franzén S, et al.: Late side effects of chemotherapy in ovarian carcinoma. A cytogenic, hematologic, and statistical study. Cancer 1982, 49:2234–2241.

    Article  PubMed  CAS  Google Scholar 

  29. Greene MH, Moloney WC, Boice JD: Melphalan may be more potent leukemogen than cyclophosphamide. Ann Intern Med 1986, 105:360–367.

    PubMed  CAS  Google Scholar 

  30. Shell AG, Disney AP, Mathew TH, et al.: Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transpl Proc 1997, 29:825–827.

    Article  Google Scholar 

  31. Lipid Research Clinics Investigators: The Lipid Research Clinics coronary primary prevention trial: results of 6 years of post-trial follow-up. Arch Intern Med 1992, 152:1399–1410.

    Article  Google Scholar 

  32. The LIPID Study Group: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359:1379–1387.

    Article  Google Scholar 

  33. Ford I, Murray H, Packard CJ, et al.: Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007, 357:1477–1486.

    Article  PubMed  CAS  Google Scholar 

  34. Strandberg TE, Pyörälä K: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771–777.

    Article  PubMed  CAS  Google Scholar 

  35. Rosseb: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343–1356.

    Article  Google Scholar 

  36. Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357–1366.

    Article  PubMed  CAS  Google Scholar 

  37. Alsheikh-Ali AA, Karas RH: Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009 (in press).

  38. Halleck M, Davis HR, Kirschmeier P, et al.: An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 2009 (in press).

  39. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360–381.

    Article  Google Scholar 

  40. Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641–651.

    Article  PubMed  CAS  Google Scholar 

  41. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.

    Article  PubMed  CAS  Google Scholar 

  42. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21–27.

    Google Scholar 

  43. FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.

    Article  Google Scholar 

  44. Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. I Reduction in incidence of coronary heart disease. JAMA 1984, 251:351–364.

    Article  Google Scholar 

  45. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  46. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/Tex-CAPS. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  47. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  48. Sever PS, Dahlöf B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  49. Colhoun HM, Beteridge DJ, Durrinigton PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicenter randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  50. Wanner C, Krane V, März W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248.

    Article  PubMed  CAS  Google Scholar 

  51. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCLE) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549–559.

    Article  Google Scholar 

  52. Kjekshus J, Apetrei E, Barrios V, et al.: for the CORONA group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248–2261.

    Article  PubMed  CAS  Google Scholar 

  53. GISSI HF Investigators: Effect of rosuvastatin in patients with chronic heart fialure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231–1239.

    Article  Google Scholar 

  54. Ridker PM, Danielson E, Fonseca FAH, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.

    Article  PubMed  CAS  Google Scholar 

  55. Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395–1407.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Preventive Medicine, Oslo University Hospital, Ullevål Kirkeveien 166, Building 19, N-0407, Oslo, Norway

    Terje R. Pedersen

Authors
  1. Terje R. Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terje R. Pedersen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, T.R. Lipid-lowering drugs and risk for cancer. Curr Atheroscler Rep 11, 350–357 (2009). https://doi.org/10.1007/s11883-009-0053-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-009-0053-3

Keywords

Search

Navigation